[{"address1": "2222 Ponce de Leon Blvd.", "address2": "Floor 3", "city": "Coral Gables", "state": "FL", "zip": "33134", "country": "United States", "phone": "786 629 1376", "website": "https://www.relmada.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sergio  Traversa M.B.A., Pharm.D.", "age": 64, "title": "CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1800723, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Maged S. Shenouda M.B.A., R.Ph.", "age": 60, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 993750, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul E. Kelly M.B.A.", "age": 67, "title": "COO & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 872780, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles S. Ence CPA, M.B.A.", "age": 59, "title": "Chief Accounting & Compliance Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 983039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gina  DiGuglielmo", "title": "VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A.", "age": 57, "title": "Chief Medical Officer of Urology", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew  Cutler", "title": "Senior Clinical Development Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard M. Mangano Ph.D.", "age": 74, "title": "Consultant", "yearBorn": 1950, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 9, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.19, "open": 4.19, "dayLow": 4.15, "dayHigh": 4.56, "regularMarketPreviousClose": 4.19, "regularMarketOpen": 4.19, "regularMarketDayLow": 4.15, "regularMarketDayHigh": 4.56, "payoutRatio": 0.0, "beta": 0.833, "forwardPE": -2.2437813, "volume": 339019, "regularMarketVolume": 339019, "averageVolume": 1092471, "averageVolume10days": 1144370, "averageDailyVolume10Day": 1144370, "bid": 4.42, "ask": 4.59, "bidSize": 11, "askSize": 11, "marketCap": 330734656, "fiftyTwoWeekLow": 0.24, "fiftyTwoWeekHigh": 5.12, "allTimeHigh": 80.0, "allTimeLow": 0.24, "fiftyDayAverage": 2.6658, "twoHundredDayAverage": 1.109725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 316848096, "profitMargins": 0.0, "floatShares": 65449524, "sharesOutstanding": 73333622, "sharesShort": 946511, "sharesShortPriorMonth": 562426, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.0128999995, "heldPercentInsiders": 0.10751, "heldPercentInstitutions": 0.18884, "shortRatio": 0.62, "shortPercentOfFloat": 0.012999999, "impliedSharesOutstanding": 73333622, "bookValue": 0.285, "priceToBook": 15.824562, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -56174540, "trailingEps": -1.78, "forwardEps": -2.01, "lastSplitFactor": "1:4", "lastSplitDate": 1569801600, "52WeekChange": 0.37082064, "SandP52WeekChange": 0.1326145, "quoteType": "EQUITY", "currentPrice": 4.51, "targetHighPrice": 10.0, "targetLowPrice": 1.0, "targetMeanPrice": 5.5, "targetMedianPrice": 5.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 13886524, "totalCashPerShare": 0.189, "totalDebt": 0, "quickRatio": 2.676, "currentRatio": 2.862, "returnOnAssets": -1.02412, "returnOnEquity": -1.9678999, "freeCashflow": -20166900, "operatingCashflow": -39990400, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RLMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Relmada Therapeutics, Inc.", "marketState": "CLOSED", "epsCurrentYear": -0.83, "priceEpsCurrentYear": -5.4337354, "fiftyDayAverageChange": 1.8442001, "fiftyDayAverageChangePercent": 0.6917999, "twoHundredDayAverageChange": 3.4002752, "twoHundredDayAverageChangePercent": 3.0640702, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "postMarketChangePercent": 1.9955581, "postMarketPrice": 4.6, "postMarketChange": 0.089999676, "regularMarketChange": 0.32, "regularMarketDayRange": "4.15 - 4.56", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1092471, "fiftyTwoWeekLowChange": 4.2700005, "fiftyTwoWeekLowChangePercent": 17.79167, "fiftyTwoWeekRange": "0.24 - 5.12", "fiftyTwoWeekHighChange": -0.60999966, "fiftyTwoWeekHighChangePercent": -0.11914056, "fiftyTwoWeekChangePercent": 37.082066, "dividendDate": 1569801600, "earningsTimestampStart": 1762462800, "earningsTimestampEnd": 1762462800, "earningsCallTimestampStart": 1763069400, "earningsCallTimestampEnd": 1763069400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.78, "epsForward": -2.01, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1403271000000, "longName": "Relmada Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1764363970, "regularMarketTime": 1764352800, "exchange": "NCM", "messageBoardId": "finmb_9070579", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 7.63724, "regularMarketPrice": 4.51, "displayName": "Relmada Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-29"}]